Posts

Insilico and Bora Unveil AI-Driven Manufacturing and CDMO Platform Plans

Insilico Medicine and Bora Pharmaceuticals announce a strategic alliance to build an AI-driven drug discovery and manufacturing platform. The collaboration aims to combine Insilico's AI-native Pharma.AI platform with Bora's global development, manufacturing, and commercialization capabilities. A new AI-driven CDMO platform will be established through a corporate venture capital model, incorporating three to five neurological-focused drug candidates from Insilico. Bora may take a 20% to 30% equity stake in the future platform; the total potential value of the multi-target partnership exceeds $2.5 billion. The alliance will use AI and automation to optimize pharmaceutical development, process optimization, manufacturing, supply chain, distribution, and quality systems, positioning Bora as a leader in AI-enabled pharmaceutical development and manufacturing. Sources: Insilico Medicine and Bora Pharmaceuticals Announce ... Bora Pharmaceuticals Partners with Insilico Me...

Celcuity Wins FDA Approval for First-in-Class Breast Cancer Drug Revtorpyk (gedatolisib)

Kelun's sac-TMT scores win in first-line PD-L1-negative NSCLC population missing from Merck's KEYTRUDA phase 3 program

AAIC 2026:Biogen公布抗tau反义寡核苷酸药物详细数据,抗tau领域初现曙光

Questions linger over Biogen's tau drug for Alzheimer's, as low dose reports better results

Autonomous Healthcare Receives FDA De Novo Marketing Authorization for Syncron-E Ventilator Waveform Analysis Software

Eisai, Biogen scoop up subQ Leqembi starter‑dose nod – FDA greenlights subcutaneous lecanemab initiation for early Alzheimer’s disease

Chai Discovery raises $400M Series C for AI molecule models used by Lilly, Novartis and Pfizer

Huyabio scores with Opdivo combo in 'milestone' skin cancer trial

AstraZeneca licenses EGFR lung cancer drug Zegfrovy from spinoff Dizal for up to $1.5B

Post-Hoc Live: What's making biotech IPOs work again?

FDA Proposes Streamlined Requirements for Hub‑and‑Spoke Drug Manufacturing Models

Biopharma Job Market Report Q2 2026: Hiring Rebounds, Layoffs Ease, AI and R&D Talent in High Demand